By Fineline Cube Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its novel bispecific antibody GenSci161 has received clinical trial application (CTA) acceptance from the National Medical Products Administration (NMPA) for a new indication: connective tissue disease-associated interstitial lung disease (CTD-ILD).
Regulatory Milestone
| Agency | Approval Type | Product | Indication | Date | Next Steps |
|---|---|---|---|---|---|
| NMPA (China) | CTA Acceptance | GenSci161 | Connective tissue disease-associated interstitial lung disease (CTD-ILD) | 02 Sep 2026 | Initiation of clinical trials in CTD-ILD patients in China |
This marks another indication expansion for GenSci161 in China. The antibody had previously received NMPA clearance for clinical trials in endometriosis, moderate-to-severe hidradenitis suppurativa, and non-infectious uveitis (NIU).
Drug Profile & Mechanism of Action
- Molecule: GenSci161, a novel, fully human IgG1 bispecific antibody (BsAb)
- Classification: Category 1 therapeutic biologic in China
- Targets: Dual blockade of both subtypes of interleukin-1 (IL-1) — IL-1α and IL-1β — with a single molecule
- Mechanism: Simultaneously neutralizes IL-1α and IL-1β, inhibiting activation of downstream inflammatory signaling pathways
- Rationale in CTD-ILD: Inflammatory cytokines play a critical role in the pathogenesis of CTD-ILD, supporting the biological rationale for IL-1 dual blockade
- Pipeline breadth: Clinical-stage programs now span CTD-ILD, endometriosis, moderate-to-severe hidradenitis suppurativa, and non-infectious uveitis (NIU)
Market Impact & Outlook
- Indication expansion: The new NMPA acceptance extends GenSci161 into fibrotic lung disease, broadening its addressable patient population beyond inflammatory and autoimmune indications
- Unmet medical need: CTD-ILD remains a serious complication of connective tissue diseases with limited treatment options, creating potential room for novel mechanisms
- Differentiated mechanism: Dual targeting of IL-1α and IL-1β in one fully human antibody sets GenSci161 apart from single-cytokine inhibitors in the autoimmune and inflammation landscape
- Pipeline momentum: Multiple NMPA-cleared clinical indications strengthen the development narrative for the bispecific platform of Changchun High & New Technology
- Strategic signal: Continued regulatory progress reinforces the company’s positioning in China’s competitive biologics market for inflammatory and fibrotic diseases
Forward‑Looking Statements – This brief contains forward-looking statements regarding the clinical development and potential indications of GenSci161. Actual results may differ materially due to clinical, regulatory, and market risks. This content is for informational purposes only and does not constitute investment advice.-Fineline Info & Tech